| 张 倩,赵 敏,周子涵,曹毓佳,殷继超.痹祺胶囊联合依那西普对强直性脊柱炎患者急性时相反应物指标、血清疼痛介质和骨代谢指标的影响[J].,2023,(6):1121-1125 |
| 痹祺胶囊联合依那西普对强直性脊柱炎患者急性时相反应物指标、血清疼痛介质和骨代谢指标的影响 |
| Effects of Biqi Capsule Combined with Etanercept on Acute Phase Reactants Indexes, Serum Pain Mediators and Bone Metabolism Indexes in Patients with Ankylosing Spondylitis |
| 投稿时间：2022-07-28 修订日期：2022-08-23 |
| DOI：10.13241/j.cnki.pmb.2023.06.024 |
| 中文关键词: 痹祺胶囊 依那西普 强直性脊柱炎 急性时相反应物 疼痛介质 骨代谢指标 |
| 英文关键词: Biqi Capsule Etanercept Ankylosing spondylitis Acute phase reactants Pain mediators Bone metabolism indexs |
| 基金项目:陕西省科技厅社会发展项目（2018SF-271） |
|
| 摘要点击次数: 799 |
| 全文下载次数: 450 |
| 中文摘要: |
| 摘要 目的：探讨痹祺胶囊联合依那西普对强直性脊柱炎（AS）患者急性时相反应物指标、血清疼痛介质和骨代谢指标的影响。方法：纳入西安市第五医院2020年4月~2022年3月期间收治的96例AS患者。按照随机数字表法分为对照组（n=48）和研究组（n=48），对照组接受依那西普治疗，研究组接受痹祺胶囊联合依那西普治疗。对比两组疗效、临床症状指标[Bath强直性脊柱炎活动指数（BASDAI）、Bath强直性脊柱炎功能指数（BASFI）、Bath强直性脊柱炎计量学指数（BASMI）、视觉疼痛模拟（VAS）评分]、急性时相反应物指标[红细胞沉降率（ESR）、C反应蛋白（CRP）]、血清疼痛介质指标[前列腺素E2 (PGE2) 、P物质( SP)、多巴胺（DA），五羟色胺（5-HT）]和骨代谢指标[骨形态发生蛋白-2（BMP-2）、骨钙素（BGP）]，观察两组不良反应发生情况。结果：研究组（95.83%）的临床总有效率高于对照组（79.17%），差异有统计学意义（P<0.05）。两组治疗后PGE2、SP、DA、5-HT下降，且研究组的下降程度更大（P<0.05）。两组治疗后CRP、ESR下降，且研究组的下降程度更大（P<0.05）。两组治疗后BMP-2、BGP升高，且研究组的升高程度更大（P<0.05）。两组治疗后BASDAI、BASFI、BASMI、VAS评分下降，且研究组的下降程度更大（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：痹祺胶囊联合依那西普治疗AS患者，疗效较好，可改善临床症状，调节急性时相反应物指标、血清疼痛介质和骨代谢指标水平，安全性较高。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of Biqi capsule combined with etanercept on acute phase reactant indexes, serum pain mediators and bone metabolism indexes in patients with ankylosing spondylitis (AS). Methods: 96 AS patients admitted to Xi'an Fifth Hospital from April 2020 to March 2022 were included. According to the random number table method, they were divided into control group (n=48) and study group (n=48). The control group was treated with etanercept, and the study group was treated with Biqi capsule combined with etanercept. The efficacy, clinical symptom indexes [Bath ankylosing spondylitis activity index (BASDAI), Bath ankylosing spondylitis function index (BASFI), Bath ankylosing spondylitis measurement index (BASMI), visual pain simulation (VAS) score], acute phase reactant indexes [erythrocyte sedimentation rate (ESR), C reactive protein (CRP)], serum pain mediators indexes [prostaglandin E2 (PGE2), substance P (SP), dopamine (DA), 5-hydroxytryptamine (5-HT)] and bone metabolism indexes [bone morphogenetic protein-2 (BMP-2), osteocalcin (BGP)] of the two groups were compared, and the occurrence of adverse reactions were observed in the two groups. Results: The total clinical effective rate of the study group (95.83%) was higher than that of the control group (79.17%), with a statistically significant difference (P<0.05). After treatment, PGE2, SP, DA, 5-HT decreased in two groups, and the degree of decline in the study group was greater (P<0.05). After treatment, CRP and ESR in two groups decreased, and the degree of decline in the study group was greater (P<0.05). BMP-2 and BGP were increased in the two groups after treatment, and the degree of increase in the study group was greater (P<0.05). After treatment, the scores of BASDAI, BASFI, BASMI and VAS in the two groups decreased, and the degree of decline in the study group was greater (P<0.05). There was no difference in incidence of adverse reactions between two groups (P>0.05). Conclusion: Biqi capsule combined with etanercept is effective in the treatment of patients with AS, which can improve clinical symptoms, regulate the levels of acute phase reactants indexes, serum pain mediators and bone metabolism indexes, and which has high safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
